Site search

Clear filter
2860 results for '' found
A Phase 3, multicentre, randomized, double-blind, placebo controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s disease (RPC01-3203) (NCT03464097)
A Phase 3, multicentre, randomized, double-blind, placebo controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s disease (RPC01-3203) (NCT03464097)
/
A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)
A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)
/
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease (NCT03467958)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease (NCT03467958)
/
INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (NCT03440372
INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (NCT03440372
/
Red Blood Cell Transfusion in ECMO - a feasibility trial (NCT05814094)
Red Blood Cell Transfusion in ECMO - a feasibility trial (NCT05814094)
/
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Derma
/
Reduction Of Chronic Post-surgical Pain with Ketamine - ROCKet Trial (ACTRN12617001619336)
Reduction Of Chronic Post-surgical Pain with Ketamine - ROCKet Trial (ACTRN12617001619336)
/
A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cance
A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cance
/
An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (NCT04905693)
/
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke w
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke w
/
25 26 27 28 29